Antisense therapy for cancer--the time of truth (Q34992794)

5 August 2017

1 reference

title

Antisense therapy for cancer--the time of truth (English)

1 reference

5 August 2017

Burkhard Jansen

1

1 reference

5 August 2017

Uwe Zangemeister-Wittke

series ordinal

2

1 reference

5 August 2017

publication date

1 November 2002

1 reference

Lancet Oncology Commission

5 August 2017

published in

1 reference

5 August 2017

volume

3

1 reference

5 August 2017

issue

11

1 reference

5 August 2017

page(s)

672-683

1 reference

Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(02)00903-8

7 January 2021

Synthesis of ribonucleosides and diribonucleoside phosphates containing 2-chloro-ethylamine and nitrogen mustard residues

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(02)00903-8

7 January 2021

Structural gene identification and mapping by DNA-mRNA hybrid-arrested cell-free translation

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(02)00903-8

7 January 2021

Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(02)00903-8

7 January 2021

Site specific enzymatic cleavage of RNA

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(02)00903-8

7 January 2021

Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(02)00903-8

7 January 2021

Induction of Apoptosis in Small-Cell Lung Cancer Cells by an Antisense Oligodeoxynucleotide Targeting the Bcl-2 Coding Sequence

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(02)00903-8

7 January 2021

Selecting effective antisense reagents on combinatorial oligonucleotide arrays

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(02)00903-8

7 January 2021

Mapping of RNA accessible sites for antisense experiments with oligonucleotide libraries

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(02)00903-8

7 January 2021

Expanded sequence dependence of thermodynamic parameters improves prediction of RNA secondary structure

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(02)00903-8

7 January 2021

Tetranucleotide GGGA motif in primary RNA transcripts. Novel target site for antisense design

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(02)00903-8

7 January 2021

Molecular mechanisms of antisense drugs: RNase H.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(02)00903-8

7 January 2021

Importance of nucleotide sequence and chemical modifications of antisense oligonucleotides

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(02)00903-8

7 January 2021

Mechanisms and therapeutic applications of immune stimulatory cpG DNA.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(02)00903-8

7 January 2021

Effects of phosphorothioate capping on antisense oligonucleotide stability, hybridization and antiviral efficacy versus herpes simplex virus infection

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(02)00903-8

7 January 2021

Mixed backbone antisense oligonucleotides: design, biochemical and biological properties of oligonucleotides containing 2'-5'-ribo- and 3'-5'-deoxyribonucleotide segments

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(02)00903-8

7 January 2021

Potent and nontoxic antisense oligonucleotides containing locked nucleic acids

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(02)00903-8

7 January 2021

Antitumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to the RIalpha subunit of protein kinase A after oral administration

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(02)00903-8

7 January 2021

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(02)00903-8

7 January 2021

The Bcl-2 protein family: arbiters of cell survival

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(02)00903-8

7 January 2021

The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(02)00903-8

7 January 2021

Is irrelevant cleavage the price of antisense efficacy?

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(02)00903-8

7 January 2021

BCL-2 antisense therapy in patients with non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(02)00903-8

7 January 2021

Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(02)00903-8

7 January 2021

bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(02)00903-8

7 January 2021

Chemosensitisation of malignant melanoma by BCL2 antisense therapy

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(02)00903-8

7 January 2021

bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(02)00903-8

7 January 2021

Induction of apoptosis in lung-cancer cells following bcl-xL anti-sense treatment.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(02)00903-8

7 January 2021

Bcl-xl antisense treatment induces apoptosis in breast carcinoma cells

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(02)00903-8

7 January 2021

Induction of endogenous Bcl-xS through the control of Bcl-x pre-mRNA splicing by antisense oligonucleotides

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(02)00903-8

7 January 2021

Activity of a novel bcl-2/bcl-xL-bispecific antisense oligonucleotide against tumors of diverse histologic origins.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(02)00903-8

7 January 2021

Antisense therapy in oncology: new hope for an old idea?

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(02)00903-8

7 January 2021

Activation of the MAP kinase pathway by the protein kinase raf

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(02)00903-8

7 January 2021

Effect of antisense c-raf-1 on tumorigenicity and radiation sensitivity of a human squamous carcinoma.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(02)00903-8

7 January 2021

Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A).

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(02)00903-8

7 January 2021

Protein kinase A (PK-A) regulatory subunit expression in colorectal cancer and related mucosa

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(02)00903-8

7 January 2021

Cooperative inhibition of renal cancer growth by anti-epidermal growth factor receptor antibody and protein kinase A antisense oligonucleotide

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(02)00903-8

7 January 2021

Ex Vivo Treatment of Bone Marrow with Phosphorothioate Oligonucleotide OL(l)p53 for Autologous Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndrome

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(02)00903-8

7 January 2021

A novel MDM2 anti-sense oligonucleotide has anti-tumor activity and potentiates cytotoxic drugs acting by different mechanisms in human colon cancer.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(02)00903-8

7 January 2021

Viral myb oncogene encodes a sequence-specific DNA-binding activity.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(02)00903-8

7 January 2021

Relationship between the c-myb locus and the 6q-chromosomal aberration in leukemias and lymphomas

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(02)00903-8

7 January 2021

Regulation of DNA methylation by the Ras signaling pathway

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(02)00903-8

7 January 2021

Inhibition of tumorigenesis by a cytosine-DNA, methyltransferase, antisense oligodeoxynucleotide

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(02)00903-8

7 January 2021

Suppression of Philadelphia1 leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(02)00903-8

7 January 2021

Clusterin Has Chaperone-like Activity Similar to That of Small Heat Shock Proteins

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(02)00903-8

7 January 2021

Control of apoptosis and mitotic spindle checkpoint by survivin

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(02)00903-8

7 January 2021

Cisplatin (CDDP) sensitizes human osteosarcoma cell to Fas/CD95-mediated apoptosis by down-regulating FLIP-L expression.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(02)00903-8

7 January 2021

Selective depletion of heat shock protein 70 (Hsp70) activates a tumor-specific death program that is independent of caspases and bypasses Bcl-2.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(02)00903-8

7 January 2021

Mutations of the BRAF gene in human cancer

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(02)00903-8

7 January 2021

Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(02)00903-8

7 January 2021

10.1016/S1470-2045(02)00903-8

Identifiers

DOI

1 reference

5 August 2017

1 reference